Gold Prices Steadied Above A Major Support Level On Monday As Growing Risks Of An Economic Recession Spurred Some Safe Haven Demand For The Yellow Metal. Prices also recovered marginally from a bruising September, where they dropped 3%. Bullion prices marked their worst quarter since March 2021 with a 7.5% drop Spot gold rose 0.2% to $1,663.99 an ounce, while gold futures were flat around $1,672 an ounce by 20:31 ET (00:31 GMT). Prices of…
In what will be the first COVID-19 jab for the adolescent population in India, the Zydus Cadila vaccine is likely to get a nod from the Centre soon.
ZyCoV-D is likely to get an emergency use authorisation this week, sources told ANI.
Zydus Cadila’s jab will be the sixth COVID-19 vaccine to get approved in India after Covishield, Covaxin, Sputnik V, Moderna and J&J, which was the latest to get DGCI nod on August 7.
Zyduc Cadila had on July 1 said that it filed an application with the Drug Controller General of India (DCGI) seeking emergency use authorisation (EUA) of ZyCoV-D. It pans to manufacture 10-12 crore doses annually.
The company had said its COVID-19 vaccine ZyCoV-D demonstrated 66.6 percent efficacy against symptomatic RT-PCR positive cases in the interim analysis. It has also told the DGCI that ZyCoV-D is safe for children aged 12 to 18 years.
It is a three-dose, intradermal vaccine which is applied using the PharmaJet needle-free system. It can be stored at 2-8 degree Celsius but has shown good stability at temperatures of 25 degree Celsius for at least three months.
The Centre had on June 27 in an affidavit told the Supreme Court that Zydus Cadila’s vaccine candidate, “will be available for 12-18 age group soon, subject to the statutory permissions”.
It informed the court that Zydus Cadila, which is developing DNA vaccines, has concluded its clinical trial for between the age group of 12 to 18 years of age. “Subject to the statutory permissions, it may be available in near future for children of the age group of 12 to 18 years of age,” it added.